Pancreatic cancer is one of the most aggressive and with less healing percentage. In Europe, pancreatic cancer is the seventh most common cancer, and represents 2.9% of cancer in men and 3.2% in women. It is also the fifth most important cause of death for cancer in Europe. The diagnosis is rare before age 45. In 80% of cases it occurs in ages between 60 and 80 years. It has a high mortality rate, mainly due to the fact that most patients (<50%) have a metastatic disease diagnosis, with a median survival of only 7-11 months. 30% -40% of patients have localized but non-resectable disease, with survival of 11-18 months. The survival rate for the first year is low, around 11-2 8% and less than 6% survive at 5 years. The purpose of the treatment is palliative to achieve improvements in symptomatology and the quality of life of the patients and extend their survival. Three types, infiltrating ductal adenocarcinoma, carcinoma of acinar cells and pancreatoblastoma are described (mainly in children). Adenocarcinoma is the most frequent subtype (> 90%).
Paclitaxel; Adenocarcinoma; Palliative treatment
Paclitaxel unit a l'albúmina: tractament de primera línia del càncer de pàncrees metastàtic. Barcelona: Servei Català de la Salut; 2018.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/3660
This item appears in following collections
The following license files are associated with this item: